Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Other Operating Expenses (2016 - 2025)

Integra Lifesciences Holdings' Other Operating Expenses history spans 16 years, with the latest figure at $217.8 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 10.41% year-over-year to $217.8 million; the TTM value through Dec 2025 reached $1.3 billion, up 77.38%, while the annual FY2025 figure was $1.3 billion, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $217.8 million at Integra Lifesciences Holdings, up from $198.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $721.4 million in Q2 2025 and bottomed at -$703000.0 in Q2 2021.
  • The 5-year median for Other Operating Expenses is $174.7 million (2023), against an average of $163.6 million.
  • The largest annual shift saw Other Operating Expenses soared 25875.78% in 2023 before it grew 7.83% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at -$169000.0 in 2021, then skyrocketed by 481.07% to $644000.0 in 2022, then skyrocketed by 25875.78% to $167.3 million in 2023, then grew by 17.94% to $197.3 million in 2024, then grew by 10.41% to $217.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Other Operating Expenses are $217.8 million (Q4 2025), $198.8 million (Q3 2025), and $721.4 million (Q2 2025).